Gene Therapy Guidance Urges 15-Year Follow-Up, With Five "Close" Years
Executive Summary
FDA's draft guidance on gene therapy studies follows the recommendations of the Biological Response Modifiers Advisory Committee in calling for 15 years of follow-up for patients
You may also be interested in...
Gene Therapy 15-Year Follow-Up In Four AE Categories Suggested By Cmte.
Gene therapy clinical trial subjects should be followed in four adverse event categories for 15 years, FDA's Biological Response Modifiers Advisory Committee recommended Oct. 24.
Gene Therapy Long-Term Follow-Up Should Include Patient Postcards - Cmte.
Gene therapy clinical trial sponsors should send an annual postcard to all patients beginning five years after the completion of a study as long-term follow-up, FDA's Biological Response Modifiers Advisory Committee recommended Nov. 17.
FDA Gene Therapy Survey Seeks Info On Quality Controls & Monitoring
FDA is gathering information on the state of the art in gene therapy research through a survey of clinical investigators.